From Hype to P&L: Hospitals Now Buying AI That Pays

Executive Summary

• Ventripoint Diagnostics appointed David Swetlow as Chief Financial Officer to strengthen financial and commercial execution of its AI‑enabled cardiac imaging platform.
• The company announced a shift toward a Device‑as‑a‑Service subscription model and highlighted growing qualified leads in Europe and North America, plus renewed capital from distributor AngioPro.
• A recent collaboration with Providence Health Care Ventures will pilot the VMS+ platform at St. Paul’s Hospital to evaluate AI‑enhanced echocardiography’s ability to reduce cardiac MRI demand, with implementation slated for early 2026.

Key Details

• CFO Appointment: David Swetlow, with >25 years senior‑management experience in med‑tech and life sciences, effective immediately.
• Strategic Rationale: CFO hire supports a refreshed commercial strategy aimed at scaling VMS+, strengthening global partnerships, and driving revenue growth.
• CEO Quote: “This is a pivotal moment for Ventripoint… David’s leadership will play a vital role as we execute on a refreshed commercial strategy…” – Hugh MacNaught, President & CEO.
• CFO Quote: Emphasized the need to evolve financial and commercial foundations to scale VMS+ globally and expand indications.
• Collaboration: Late‑October partnership with Providence Health Care Ventures to validate VMS+ at St. Paul’s Hospital (Vancouver). Study will assess AI‑enhanced echo’s capacity to cut cardiac MRI demand; implementation expected early 2026.
• Business Model Update: Transition to a Device‑as‑a‑Service subscription model intended to shorten sales cycles and generate recurring revenue.
• Market traction: Qualified leads increasing in Europe & North America; European distributor AngioPro recommitted capital and support.
• Regulatory status: FDA clearance, Health Canada licensing, EU MDR certification maintained; successful quality audits in September with zero major non‑conformities.
• Technology Highlight: VMS+ creates 3D heart models from standard 2D ultrasound, delivering measurements clinically comparable to MRI.

Notable Quotes

• “The VMS+ technology platform stands at the forefront of cardiac imaging innovation… to enhance care and reduce anxious wait times for at‑risk cardiac patients,” – David Swetlow, CFO.
• “Implementation at St. Paul’s is expected to begin in early 2026,” – Company statement.